Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

Background: There is little data on the outcome of cabazitaxel (CBZ) treatment of elderly patients with castration-resistant prostate cancer (CRPC). This study assessed the efficacy and safety of CBZ chemotherapy in patients with CRPC aged 75 years or older in a multiinstitutional study. Methods: We...

Full description

Bibliographic Details
Main Authors:	Takashi Matsumoto, Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	Prostate International
Subjects:	Cabazitaxel Castration-resistant prostate cancer Efficacy Safety The elderly
Online Access:	http://www.sciencedirect.com/science/article/pii/S228788822030088X

Similar Items

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
by: Nicolas Delanoy, et al.
Published: (2021-03-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
by: Vanita Noronha, et al.
Published: (2016-08-01)

Physicochemical stability of Cabazitaxel Zentiva® solution in vials after opening and diluted solutions in three infusion bags
by: D’Huart Elise, et al.
Published: (2023-07-01)

Cabazitaxel liposomes with aptamer modification enhance tumor‑targeting efficacy in nude mice
by: Cheng, Yuzhu, et al.
Published: (2019)

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
by: Filippos Koinis, et al.
Published: (2023-09-01)

Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel
by: Fanchao Meng, et al.
Published: (2019-10-01)

Topical Drug Delivery of Concentrated Cabazitaxel in an α‐Tocopherol and DMSO Solution
by: Boyang Sun, et al.
Published: (2023-10-01)

Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
by: Hideyasu Matsuyama, et al.
Published: (2023-06-01)

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel
by: Sandra M. Rocha, et al.
Published: (2023-04-01)

Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry
by: Zafar Malik, et al.
Published: (2020-04-01)

Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects
by: Nagavendra Kommineni, et al.
Published: (2019-03-01)

Reduction-Responsive Stearyl Alcohol-Cabazitaxel Prodrug Nanoassemblies for Cancer Chemotherapy
by: Yuting Liu, et al.
Published: (2023-01-01)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
by: Anders Bjartell, et al.
Published: (2022-11-01)

Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
by: Mário Sousa-Pimenta, et al.
Published: (2023-05-01)

Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants
by: Valsalakumari R, et al.
Published: (2024-03-01)

Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin
by: Shigeaki Katsumi, et al.
Published: (2023-07-01)

Influence of unsaturated fatty acids on the antitumor activity of polymeric conjugates grafted with cabazitaxel against prostate cancer
by: Hongshuai Lv, et al.
Published: (2023-12-01)

Fine-tuning the activation behaviors of ternary modular cabazitaxel prodrugs for efficient and on-target oral anti-cancer therapy
by: Mingyang Zhang, et al.
Published: (2024-04-01)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
by: Shigetomo Yamada, et al.
Published: (2022-03-01)

Cabazitaxel-Loaded Nanoparticles Reduce the Invasiveness in Metastatic Prostate Cancer Cells: Beyond the Classical Taxane Function
by: Jana B. Lampe, et al.
Published: (2023-02-01)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
by: Sotaro Chikamatsu, et al.
Published: (2022-03-01)

Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes
by: Isil Ezgi Eryilmaz, et al.
Published: (2024-12-01)

Comparison of clinical-economic evaluation of cabazitaxel and abiraterone for prostate cancer based on the results of clinical trials and real world data
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Cabazitaxel-loaded human serum albumin nanoparticles combined with TGFβ-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer
by: Tiantian Tan, et al.
Published: (2023-07-01)

Review: castration – animal welfare considerations
by: Gabriela A. Marquette, et al.
Published: (2023-12-01)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
by: Matsumoto T, et al.
Published: (2022-08-01)

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
by: Takehiko Nakasato, et al.
Published: (2020-03-01)

A COPARATIVE STUDY OF CASTRATION IN PIGS
by: R. N.Al-Asadi,, et al.
Published: (1992-06-01)

Reasons for and Behavioral Consequences of Male Dog Castration—A Questionnaire Study in Poland
by: Marcelina Kriese, et al.
Published: (2022-07-01)

Post-castration syndrome: relevance, impact on quality of life, methods of correction
by: A. M. Ziganshin, et al.
Published: (2024-03-01)

Chemical Castration for Pedophiles: Study of Fiqh Problems in Indonesia
by: Azhari Akmal Tarigan
Published: (2020-10-01)

CHEMICAL CASTRATION FROM CRIMINAL LAW AND HUMAN RIGHTS
by: Dina Silvia Puteri, et al.
Published: (2020-06-01)

Post-castration variations in weight gain in a cohort of young adult male cats*
by: Alfreda Wei, et al.
Published: (2014-01-01)

Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides
by: Søren Brøgger Christensen
Published: (2022-09-01)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
by: Minyong Kang, et al.
Published: (2015-12-01)

THERMAL CASTRATION AS A METHOD OF GAMETOPHYTIC SELECTION TO INCREASE ADAPTABILITY
by: A. N. Borovik, et al.
Published: (2018-05-01)

SURGICAL REPORT: PARTIAL BILATERAL MASTECTOMY AND CASTRATION IN A DOG
by: Grazielly Diniz Duarte, et al.
Published: (2022-08-01)